Davidson Kempner Capital Management LP Invests $265,000 in Gracell Biotechnologies Inc. (NASDAQ:GRCL)

Davidson Kempner Capital Management LP acquired a new position in shares of Gracell Biotechnologies Inc. (NASDAQ:GRCL) during the 1st quarter, HoldingsChannel.com reports. The fund acquired 17,500 shares of the company’s stock, valued at approximately $265,000.

Several other large investors also recently bought and sold shares of GRCL. BlackRock Inc. bought a new position in shares of Gracell Biotechnologies during the 1st quarter worth about $14,699,000. Federated Hermes Inc. bought a new position in shares of Gracell Biotechnologies during the 1st quarter worth about $18,340,000. New Silk Road Investment PTE Ltd. bought a new stake in Gracell Biotechnologies in the first quarter valued at about $770,000. Capital International Investors bought a new stake in Gracell Biotechnologies in the first quarter valued at about $17,287,000. Finally, Indus Capital Partners LLC bought a new stake in Gracell Biotechnologies in the first quarter valued at about $1,329,000. Institutional investors own 30.94% of the company’s stock.

Separately, Zacks Investment Research cut shares of Gracell Biotechnologies from a “buy” rating to a “hold” rating in a research note on Monday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $30.20.

NASDAQ GRCL opened at $11.88 on Thursday. The company has a 50-day simple moving average of $13.35. Gracell Biotechnologies Inc. has a twelve month low of $9.75 and a twelve month high of $33.70. The company has a current ratio of 18.38, a quick ratio of 18.38 and a debt-to-equity ratio of 0.02.

Gracell Biotechnologies (NASDAQ:GRCL) last released its quarterly earnings results on Sunday, May 16th. The company reported ($0.25) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.04). As a group, research analysts anticipate that Gracell Biotechnologies Inc. will post -0.25 earnings per share for the current fiscal year.

Gracell Biotechnologies Profile

Gracell Biotechnologies Inc, a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia.

See Also: Strangles

Want to see what other hedge funds are holding GRCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gracell Biotechnologies Inc. (NASDAQ:GRCL).

Institutional Ownership by Quarter for Gracell Biotechnologies (NASDAQ:GRCL)

Receive News & Ratings for Gracell Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gracell Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.